We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-2.82%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.01B
AUM Growth
-$1.6B
(-35%)
Cap. Flow
-$1.27B
Cap. Flow
% of AUM
-42.02%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$89.8M |
| 2 |
Becton Dickinson
BDX
|
+$70.5M |
| 3 |
Zoetis
ZTS
|
+$66.8M |
| 4 |
Merck
MRK
|
+$64.8M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$60.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$218M |
| 2 |
argenx
ARGX
|
+$127M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$125M |
| 4 |
Boston Scientific
BSX
|
+$113M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$100M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RNAM
51
DELISTED
Avidity Biosciences
RNAM
| $19.4M | 0.64% |
1,265,545
-2,009,455
| -61% | -$44.2M |
|
52
Vaxcyte
PCVX
$7.78B
| $19.1M | 0.63% |
510,000
-1,105,400
| -68% | -$46.9M |
|
53
Arcutis Biotherapeutics
ARQT
$3.49B
| $17.9M | 0.59% |
1,628,500
-126,500
| -7% | -$1.83M |
|
|
VRNA
54
DELISTED
Verona Pharma
VRNA
| $17.6M | 0.59% |
+878,800
| New | +$19M |
|
|
PNT
55
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $17.5M | 0.58% |
2,411,600
-20,800
| -0.9% | -$154K |
|
56
DexCom
DXCM
$28.9B
| $17.2M | 0.57% |
148,000
-608,800
| -80% | -$68.1M |
|
57
BridgeBio Pharma
BBIO
$16.7B
| $16.6M | 0.55% |
+1,000,000
| New | +$11.7M |
|
58
Immunovant
IMVT
$7.93B
| $16.2M | 0.54% |
+1,043,000
| New | +$18.1M |
|
59
Intellia Therapeutics
NTLA
$1.51B
| $15.5M | 0.52% |
417,000
-221,200
| -35% | -$8.68M |
|
60
Caribou Biosciences
CRBU
$148M
| $14.6M | 0.49% |
2,758,600
-124,000
| -4% | -$772K |
|
61
Phathom Pharmaceuticals
PHAT
$939M
| $14.6M | 0.49% |
2,048,600
+148,600
| +8% | +$1.31M |
|
|
MRSN
62
DELISTED
Mersana Therapeutics
MRSN
| $14.1M | 0.47% |
+137,329
| New | +$19.3M |
|
63
Natera
NTRA
$36B
| $13.9M | 0.46% |
249,900
-1,549,000
| -86% | -$74.3M |
|
64
Twist Bioscience
TWST
$5.42B
| $12.4M | 0.41% |
819,000
+208,000
| +34% | +$4.59M |
|
65
Collegium Pharmaceutical
COLL
$1.17B
| $9.25M | 0.31% |
385,500
+347,602
| +917% | +$9.22M |
|
66
Cytokinetics
CYTK
$10.8B
| $8.87M | 0.29% |
252,000
-168,700
| -40% | -$6.88M |
|
|
ALPN
67
DELISTED
Alpine Immune Sciences Inc
ALPN
| $7.64M | 0.25% |
989,500
-38,700
| -4% | -$308K |
|
|
KNTE
68
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $7.25M | 0.24% |
1,160,000
-52,700
| -4% | -$321K |
|
69
AN2 Therapeutics
ANTX
$167M
| $7.14M | 0.24% |
723,200
-20,400
| -3% | -$227K |
|
70
Compass Therapeutics
CMPX
$360M
| $5.97M | 0.2% |
1,825,000
-175,000
| -9% | -$687K |
|
71
Altimmune
ALT
$576M
| $5.55M | 0.18% |
1,315,200
-2,674,800
| -67% | -$31.8M |
|
72
Geron
GERN
$911M
| $4.62M | 0.15% |
+2,128,000
| New | +$6.04M |
|
73
Century Therapeutics
IPSC
$361M
| $4.4M | 0.15% |
1,268,100
-35,500
| -3% | -$156K |
|
|
SGMO
74
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $4.35M | 0.14% |
2,470,000
-278,300
| -10% | -$794K |
|
75
Praxis Precision Medicines
PRAX
$8.17B
| $3.46M | 0.12% |
+285,447
| New | +$12M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q1 2023 Portfolio in Review
As of Q1 2023, Avidity Partners Management held 106 positions worth $3.01B, down 35% from $4.62B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Avidity Partners Management withdrew a net $1.27B in Q1 2023, closing 23 positions and reducing 41 holdings. Its most notable exit was United Therapeutics, an estimated $218M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier, followed by Financials.
Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $97.9M.
- Avidity Partners Management's largest Q1 2023 buy was Regeneron Pharmaceuticals: 119,100 shares worth $97.9M.
- Avidity Partners Management added most to Bio-Rad Laboratories Class A in Q1 2023, an estimated $60.5M increase.
- Avidity Partners Management's biggest Q1 2023 reduction was argenx, cutting an estimated $127M.
- Avidity Partners Management fully exited United Therapeutics in Q1 2023, selling an estimated $218M.
- Avidity Partners Management's ten largest holdings make up 33% of its $3.01B portfolio in Q1 2023.
- Avidity Partners Management opened 21 new positions and closed 23 in Q1 2023.
- Avidity Partners Management's portfolio value fell 35% quarter-over-quarter to $3.01B.
Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.